-+ 0.00%
-+ 0.00%
-+ 0.00%

VistaGen Therapeutics Q3 EPS $(0.46) Beats $(0.51) Estimate, Sales $234.00K Beat $180.00K Estimate

Benzinga·02/13/2025 21:42:19
Listen to the news
VistaGen Therapeutics (NASDAQ:VTGN) reported quarterly losses of $(0.46) per share which beat the analyst consensus estimate of $(0.51) by 9.8 percent. This is a 109.09 percent decrease over losses of $(0.22) per share from the same period last year. The company reported quarterly sales of $234.00 thousand which beat the analyst consensus estimate of $180.00 thousand by 30.00 percent. This is a 43.12 percent decrease over sales of $411.40 thousand the same period last year.